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Sir, A 30-year-old unmarried male presented to skin outpatient department with lesions over the body for 5 months with no history of any drug or food allergies, joint pain, and fever or photoaggravation. The patient had a history of sexual exposure, several times, with a known female partner. Cutaneous examination revealed multiple, well-defined, reddish-orange plaques with multiple follicular hyperkeratotic papules over upper limbs, knees, and trunk with islands of normal skin within the lesions [Figures 1a-e]. All the fingernails had multiple irregular pits. The scalp, oral cavity, and genitals were normal. He was treated as a case of psoriasis by a private practitioner with tablet methotrexate 7.5 mg/week for 2 months.
All routine investigations were normal. Serology testing for HIV 1 and 2 was positive by enzyme-linked immunosorbent assay. Skin biopsy revealed moderate acanthosis, short and broadened rete ridges, moderate spongiosis with alternate layers of parakeratosis and orthokeratosis, and thick suprapapillary plates. Superficial dermis showed orthokeratotic plug and mild perivascular lymphoplasmacytic inflammatory infiltrate [ Figure 2 ]. Changes were suggestive of pityriasis rubra pilaris (PRP). The patient was started on antiretroviral drugs following which there was improvement in the lesions.
PRP is a papulosquamous disorder of unknown etiology which progresses to erythroderma with keratoderma of the palms and soles. The disease was originally classified by Griffiths into five groups. A sixth group was then introduced to accommodate those with HIV infection, which appears to differ from the classic forms. [1] PRP Type 6 is characterized by the presence of HIV infection, usually without evidence of immunosupression, a poor prognosis, a poor response to etretinate, and variable association with lesions of acne conglobata, hidradenitis suppurativa, and lichen spinulosus. [2] It commonly affects young homo-or heterosexual males. The pathogenesis of PRP may be related to abnormal immune response to antigenic triggers, that is, HIV and follicular inflammation caused by infection of the hair bulge region by HIV. Vitamin A deficiency, deficiency of retinol-binding protein, and genetic factor can also be the cause. [3] There is no single diagnostic laboratory test or genetic marker for the diagnosis of PRP. It can be diagnosed on a clinical suspicion and dermatopathological correlation as seen in our patient. The disease can be designated by the wider term HIV-associated follicular syndrome or HIV-associated follicular occlusion triad, as nodulocystic folliculitis sets this disorder apart from classic PRP. [4] Cases of PRP in association with HIV have been reported. [3, 5, 6] In the documented cases, the onset of PRP occurred shortly after or at the same time when the patients tested positive for HIV infection. In our case, HIV infection was a retrospective diagnosis. Neither the patient knew about his HIV status nor it was clear to the clinician as to whether there was immunosuppression before the onset of the lesions or it developed following the development of the lesions which could be accidental. Acne conglobata and hidradenitis suppurativa which used to be present with HIV-associated PRP were absent in our patient.
The main line of treatment for Type 6 PRP is antiretroviral drugs, which cause alleviation of the symptoms and may even cause complete regression in many patients, [6] as was seen in our patient after 3 months.
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Sir, World Health Organization (WHO) has introduced multidrug therapy (MDT) for leprosy since 1983 and later made it fixed duration treatment. Still later, the WHO has reduced the duration of multibacillary (MB) MDT regimen from 24 months to 12 months and eliminated the need for follow-up visit and slit-skin smear examination. Although fixed duration treatment has led to massive organizational success and resultant decrease in prevalence and annual case detection rate, follow-up data after completion of WHO MDT are largely lacking particularly from this part of the world.
[1] So, we, in a tertiary care center of eastern India, conducted a study among patients who have completed WHO MDT 6 months to 2 years earlier for assessment of clinical, microbiological, and quality of life (QoL). We evaluated the patients for clinical improvement, episodes of reaction, appearance of new lesions, status of slit-skin smear, and overall QoL using Bengali and Hindi versions of Dermatology Life Quality Index (DLQI) scale. We also performed DNA polymerase chain reaction (PCR) for Mycobacterium leprae from the patients' tissues to find PCR positivity in these patients.
A total of 77 patients of Hansen's disease who had completed WHO MDT treatment from 6 months to 2 years earlier at our center were contacted by means of either telephonic or postal communication. These patients were asked to follow-up for evaluation. Only 25 patients turned up with the response rate being 32.4%.
Among the study participants, 21 (84%) participants were male and 4 (16%) were female. Of the 25 patients, 23 had MB and 2 had paucibacillary (PB) leprosy. The age varied from 19 years to 51 years with the mean age being 37.04. Clinically, 22 (88%) patients had borderline leprosy, 2 (8%) had tuberculoid leprosy, and 1 (4%) had lepromatous leprosy. Of these patients, 23 (92%) patients received MB MDT and 2 (8%) PB MDT [ Table 1 ].
Of 25 patients examined clinically, 11 patients showed complete healing, 7 patients had partial healing, and 7 presented with no sign of healing. Changes in the lesions were present in 14 patients in the form of redness, scaling, and pigmentation. Of the 7 patients who had no sign of healing, 5 presented with signs of activity and relapse in the form of appearance of new nerve involvement (2; 8%), appearance of new lesion (5; 20%), and the appearance of new deformity (1; 4%). Type 1 reaction was seen in 8 (32%) patients and Type 2 reaction in 3 (12%).
